Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
1
33%
Ph phase_1
1
33%
Ph not_applicable
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

completed267%
not_yet_recruiting133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
completednot_applicable

Using Imaging to Assess Effects of THC on Brain Activity

NCT03655717
completedphase_1

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

NCT02811939

Clinical Trials (3)

Showing 3 of 3 trials
NCT07148206Phase 3

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

Not Yet Recruiting
NCT03655717Not Applicable

Using Imaging to Assess Effects of THC on Brain Activity

Completed
NCT02811939Phase 1

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

Completed

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3